Bristol-Myers Squibb (BMY) Tops Q3 EPS by 14c, Offers FY20 and FY21 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Tops Q3 EPS by 14c, Offers FY20 and FY21 Guidance

Bristol Myers Squibb Reports Third Quarter 2020 Financial Results

November 5, 2020 6:59 AM EST

Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant Pipeline and Regulatory Milestones Achieves Positive Results from POETYK-PSO-1 Evaluating Deucravacitinib (TYK2 inhibitor) for the Treatment of Moderate to Severe Plaque Psoriasis Raises 2020 GAAP and Non-GAAP EPS Guidance; Reaffirms 2021 Non-GAAP EPS Guidance

NEW YORK--(BUSINESS... More